(S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study

• DOI: 10.1007/s40263-016-0371-2
• Publication Date: 2016-07-27T07:32:01Z
• Authors: Julia Höfler; Alexandra Rohracher; Gudrun Kalss; Georg Zimmermann; Judith Dobesberger; Georg Pilz; Markus Leitinger; Giorgi Kuchukhidze; Kevin Butz; Alexandra Taylor; Helmut Novak; Eugen Trinka
• Keywords: Refractory (planetary science); Bolus (digestion)

The aim was to describe the safety and efficacy of (S)-ketamine [(S)-KET] in a series patients with refractory super-refractory status epilepticus (RSE SRSE) specialized neurological intensive care unit (NICU). We retrospectively analyzed data RSE SRSE treated (S)-KET NICU, Salzburg, Austria, from 2011 2015. Data collection included demographic features, clinical presentation, diagnosis, electroencephalogram (EEG) data, anticonvulsant treatment, timing, duration treatment (S)-KET. Outcomes were seizure control death. A total 42 (14 women) median (SE) 10 days [first quartile (Q1) 5.0, Q3 21.0]; latency SE onset first administration 3 (Q1 2.0, 6.8). Prior administration, had received two 3.0) anesthetics three 4.0) antiepileptic drugs. Forty percent (17/42) propofol: 65 % prior (S)-KET; 35 at same time Seven bolus 200 mg 200, 250) followed by continuous infusion, while started infusion (maximum rate 2.55 mg/kg/h; Q1 2.09, 3.22). In 64 (27/42), last drug before cessation; five patients, it given propofol time. Median 4 Overall well tolerated, adverse effects not observed, overall mortality 45.2 %. Treatment adult led resolution No events found, indicating favorable profile.